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Duplex ultrasound screening detects high rates of
deep vein thromboses in critically ill trauma patients
Amir Azarbal, MD, Susan Rowell, MD, Jason Lewis, BA, Rakhee Urankar, MD, Shannon Moseley, BA,
Gregory Landry, MD, and Greg Moneta, MD, Portland, Ore
Objective: American College of Chest Physician (ACCP) guidelines stratify deep venous thrombosis (DVT) risk in trauma
patients based on injury pattern and pharmacologic prophylaxis. Screening is only recommended for patients with
high-risk injuries who are unable to receive pharmacologic prophylaxis. However, the prevalence of lower extremity DVT
(LEDVT) in trauma patients may be higher than reported in previous studies as many studies on DVT screening have not
investigated calf vein DVTs (CVDVT) and have not exclusively targeted critically ill patients. Given that current ACCP
guidelines recommend treatment of CVDVTs, we investigated the efficacy of duplex ultrasound (DUS) screening in
critically ill trauma patients for all LEDVTs, including CVDVT, regardless of injury pattern, risk factors, or pharmaco-
logic prophylaxis.
Methods: Medical records of 264 intensive care unit trauma patients who received DUS screening for LEDVT were
retrospectively examined for the presence of injuries conferring high risk for LEDVT, patient specific DVT risk factors,
and low molecular weight heparin (LMWH) prophylaxis.
Results: Forty (15.2%) patients had LEDVTs found onDUS screening, 24 (60%) were CVDVT, and 30% of all DVTs were
diagnosed within 1 week of admission. Patients without high-risk injuries receiving LMWHhad a 13.5%DVT rate, which
did not differ significantly from the 19.7% DVT rate in high-risk injury patients not receiving LMWH (P  .667).
Conclusions: Lower extremity DVT is common in critically ill trauma patients, particularly in the first week following
injury, regardless of injury pattern, DVT risk factors, or pharmacologic prophylaxis. Previous studies have underesti-
mated DVT rates by not investigating CVDVTs and not exclusively targeting critically ill patients. We recommend early
and continued DUS DVT screening of all critically ill trauma patients. ( J Vasc Surg 2011;54:743-8.)
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(LEDVTs) are a common and serious sequela of trauma.
DVT rates in excess of 58% have been reported in trauma
patients not receiving pharmacologic prophylaxis.1 Such
high DVT rates have resulted in aggressive prophylaxis
measures at many trauma centers consisting of pneumatic
compression devices and pharmacologic prophylaxis with
unfractionated heparin, and more recently, low molecular
weight heparin. However, despite such measures, some
studies have reported continued high rates of DVTs in
high-risk or criticallyillpatients.2-4 Furthermore, most
lower extremity DVTs in trauma patients are asymptomatic
and only detected with screening.5-7
American College of Chest Physicians guidelines rec-
ommend against routine ultrasound screening for lower
extremity DVTs in trauma patients except for patients who
are not candidates for pharmacologic prophylaxis and have
injuries that confer a high risk of DVT.8 This recommen-
dation is based on multiple studies demonstrating low rates
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doi:10.1016/j.jvs.2011.02.058f LEDVT in trauma patients receiving adequate pharma-
ologic prophylaxis.9-13 However, most of these studies
ave not focused exclusively on critically ill trauma patients
nd several studies have not investigated the presence of calf
ein DVTs. Given that American College of chest physician
ACCP) guidelines currently recommend treatment of calf
ein DVTs (CVDVTs), we sought to determine the utility
f our trauma system’s policy of routine DUS screening of
ll critically ill trauma patients for all lower extremity DVTs,
ncluding CVDVTs.
ETHODS
A database of all consecutive trauma entries between
anuary 2007 and December 2008 at our level 1 trauma
enter was retrospectively reviewed for patients requiring
dmission to the trauma intensive care unit. At our institu-
ion, admission to the trauma intensive care unit (ICU) is
etermined by the attending trauma surgeon. While par-
ially subjective, there are several absolute criteria for ICU
dmission: Need for pressor support, invasive hemody-
amic monitoring, any intracranial hemorrhage, cardiac
nd pulmonary contusions, need for continuous veno-
enous hemodialysis, electrocutions, solid organ injury,
elvic fracture with signs of bleeding, hemodynamic or
espiratory instability. ICU trauma admissions were then
earched for patients that underwent at least one DUS
creening examination for lower extremity DVTs. During
he study period, there were 3047 trauma entries; 997
atients required admission to the ICU, of which 264
atients underwent DUS screening.
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LEDVTs are performed routinely at our institution on a
weekly basis. Examinations are performed on Tuesdays and
Thursdays. Patients receiving DUS screening were identi-
fied as patients receiving multiple venous DUS examina-
tions on consecutive Tuesdays or Thursdays, or a single
examination on a Tuesday or Thursday without any men-
tion of specific DVT symptoms (ie, swelling, pain) or
concern for DVT on their progress note from the day of the
examination. Screening studies could be ordered on days
other than Tuesdays and Thursdays at the discretion of the
attending trauma surgeon. However, because of the inabil-
ity to determine whether these studies were performed for
symptoms or as screening studies, these studies were not
included in the analysis.
Patient variables such as age, gender, ICU length of
stay (LOS), admission Glasgow Coma Scale (GCS) scores,
injury severity score (ISS), and ethnicity were collected
from the medical records. Data on three high-risk injury
patterns—pelvic fractures, long bone fractures, and spine
injury—were collected. Data on DVT prophylaxis with low
molecular weight heparin (LMWH) and sequential com-
pression devices (SCDs) were recorded. Pharmacologic
prophylaxis was defined as administration of LMWH, at a
dose of 30 mg SC BID or 40 mg SC daily, for at least 48
hours prior to the DUS examination.
All scans examined the deep and superficial veins of the
lower extremity from the common femoral vein to the
ankle, including the peroneal, posterior tibial, gastrocne-
mius, and soleal veins. LEDVT was diagnosed in instances
of noncompressible veins, lack of respiratory variation in
above knee segments, and inadequate flow augmentation
to calf and foot compression maneuvers. DVTs were de-
fined as proximal if they occurred in the popliteal vein or
more central. Calf vein DVTs were identified as thrombosis
involving an axial calf vein or muscular vein without exten-
sion to the popliteal vein.
All US examinations were performed with a Philips IU
2200 or Philips 5500 duplex scanner (Royal Phillips Elec-
tronics, Amsterdam, The Netherlands) by a registered vas-
cular technician. Examinations were done in the ICU with
patients in the supine position without any tilting of the bed
to avoid disturbing patient monitors and drains.
The presence of long bone fractures, external hardware,
and bandages commonly lead to incomplete examinations.
For the purpose of analysis, incompletely visualized seg-
ments were considered to be free from DVT.
Statistical analysis was performed using SPSS software
version 17 (IBM, Somers, NY). Univariate analysis of age,
gender, ICU LOS, admission GCS, ISS, pelvic fracture,
long bone fracture, spine injury, and presence of LMWH
prophylaxis was performed using the Student t test and
chi-square analysis. The factors associated with develop-
ment of DVTs, the presence of LMWH prophylaxis, and
high-risk injuries were then reexamined using the categorical
or binary variables—age greater than 50, presence of a high-
risk injury, absence of LMWH prophylaxis, and abnormal
admission GCS. Combinations of variables associated with yVT development were also examined in an attempt to
dentify a patient population with a low DVT rate who may
ot benefit from duplex ultrasound screening.
ESULTS
The overall incidence of LEDVTs discovered with the
creening protocol was 15.2% (n 40/264). The majority,
0% (n  24/40), of LEDVTs in our population were calf
ein DVTs. Table I shows the correlation of patient factors
ith LEDVT development using univariate analysis. Pa-
ients developing LEDVTs were significantly older and had
ower admission GCS scores than patients who did not
evelop LEDVTs. In addition, patients with LEDVTs had a
onger ICU LOS than those who did not develop LEDVTs.
he correlation with ISS and development of LEDVTs on
creening ultrasound did not reach statistical significance (P
09). Table II shows the correlation of three high-risk injuries
ith DVT detection on DUS. None of the three examined
igh-risk injuries—long bone fracture, spine fracture, or
elvic fracture—was significantly correlated with a higher
ate of DVT development in our population.
Factors associated with development of DVTs, the
resence of LMWH prophylaxis, and high-risk injuries
ere then reexamined as binary variables: age 50 years,
resence of a high-risk injury, absence of LMWH prophy-
axis, and abnormal admission GCS score (Table III).
omparing patients with normal admission GCS scores
GCS 15) to those with abnormal admission GCS scores
GCS 15) showed a significant difference in DVT detec-
ion rates in these two groups, 13.3% vs 30.0% (P .009).
tratification of patients into age 50 years and age
able I. Comparison of continuous patient variables
mong patients with and without LEDVT
ariable DVT No DVT P
ge (year) 57.0 18.4 49.2  21.0 .029
CU LOS (days) 10.8  13.8 6.2  5.9 .041
CS 11.3  5.2 14.2  2.2 .005
SS 25.8  15.5 23.4  11.5 .099
VT, Deep venous thrombosis; GCS, Glasgow Coma Scale; ICU, intensive
are unit; ISS, injury severity score; LEDVT, lower extremity deep venous
hrombosis; LOS, length of stay.
able II. Comparison of LEDVT rates in the presence
nd absence of high-risk injuries
ariable # DVT % DVT P
ong bone fx  16/73 21.9 .058
ong bone fx  24/191 12.6
pine injury  7/44 15.9 .878
pine injury  33/220 15
elvis fx  11/57 19.3 .324
elvis fx  29/207 14
VT, Deep venous thrombosis; LEDVT, lower extremity deep venous
hrombosis.ounger than 50 years also showed a significant difference
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Volume 54, Number 3 Azarbal et al 745of DVT rates, 19.5% vs 10.7% (P .045). LMWH prophy-
laxis and the absence of a high-risk injury were not associ-
ated with lower DVT rates.
Given that no binary single variable was associated with
a DVT rate of 10%, we examined combinations of vari-
ables in an attempt to identify a patient population with a
low DVT rate who may not benefit from duplex ultrasound
screening. However, when the variables of age 50 years
and a normal GCS score were combined, we continued to
observe a 10.3% LEDVT rate. Finally, the combination of
age50 years, normal GCS score, no high-risk injury, and
LMWH prophylaxis identified a group with a 20% (n 
2/10) DVT rate.
Table IV stratifies risk of DVT development based on
ACCP guidelines for DUS screening of trauma patients.
The “highest risk” group—patients with high-risk injuries
and not receiving LMWH prophylaxis—had a 19.7% DVT
rate. This DVT rate was not significantly higher than the
DVT rate of the other three groups (P  .667).
DISCUSSION
Lower extremity DVTs are a common complication in
trauma patients. Additionally, most lower extremity DVTs
in trauma patients are unsuspected clinically.5-7 However,
the current ACCP guidelines recommend against routine
DUS screening of trauma patients unless the patients have
associated high-risk injuries and cannot receive pharmaco-
logic prophylaxis. In our study, patients in the “lowest-
risk” category according to ACCP guidelines—patients
without high-risk injuries who were receiving LMWH pro-
phylaxis—still had a 13.5% incidence of LEDVTs. While
Table III. DVT rates as a function of categorical
variables of DVT risk
Variable DVT % DVT P
Age 50 14/131 10.7 .045
Age 50 26/133 19.5
GCS  15 17/128 13.3 .009
GCS  15 15/50 30
LMWH 16/110 14.5 .776
No LMWH 24/154 15.6
No high-risk injury 15/119 12.6 .296
High-risk injury 24/145 16.6
DVT, Deep venous thrombosis; GCS, Glasgow Coma Scale; LMWH, low
molecular weight heparin.
Table IV. Incidence of DVT stratified by LMWH
prophylaxis and presence of high-risk injuries
High-risk injury No high-risk injury
LMWH 11/74 (14.9%) 5/36 (13.5%)
No LMWH 14/71 (19.7%) 10/82 (12.2%)
P  .667
DVT, Deep venous thrombosis; LMWH, low molecular weight heparin.age50 years and a normal GCS score were associated with Dower DVT rates, neither of these factors, alone or in
ombination, was able to predict a DVT rate of 10%.
The current recommendation for pharmacologic pro-
hylaxis of trauma patients by ACCP is LMWH.8 Studies
ave shown the superiority of LMWH over low-dose un-
ractionated heparin (LDUH) in trauma patients. Geerts et
l demonstrated that LMWH lowers both proximal and
verall DVT rates.3 In this study, the patients were severely
njured with an ISS of approximately 23, which is very
imilar to the ISS of the patients in our study. The absolute
VT rates of the LDUH and LMWH groups were 44% and
1%, respectively. These DVT rates were lower than Geerts
t al’s previously studied, severely injured group of trauma
atients, who did not receive pharmacologic prophylaxis
nd had a DVT rate of 58%. However, the absolute DVT
ates of this severely injured group is very high regardless of
harmacologic prophylaxis and much higher than the DVT
ates of studies cited in the ACCP guidelines.5,9-13 There-
ore, while LMWH was the best pharmacologic prophylaxis
dentified by Geerts et al, it was by no means adequate or
omplete prophylaxis against LEDVTs in this severely in-
ured patient population. The decreased utility of LMWH
n preventing LEDVTs has also been demonstrated in other
linical scenarios. A randomized controlled trial of LMWH
rophylaxis for spinal cord injury showed that 60% of
atients in the LMWH prophylaxis group developed
EDVTs,14 and a meta-analysis of this group showed a
6.9% asymptomatic DVT rate in this same group despite
harmacologic prophylaxis.15
Unlike the sentinel paper by Geerts et al, LMWH
rophylaxis was not associated with lower DVT rates in our
tudy. Unlike Geerts et al’s randomized prospective design,
ur study was a retrospective analysis with its inherent
imitations. Also, while LMWH prophylaxis has been
hown to be less effective in LEDVT prophylaxis in certain
ituations as mentioned above,14,15 not enough evidence
xists to exclude it as prophylaxis against LEDVT forma-
ion in trauma patients. Therefore, LMWH continues to be
sed in all trauma patients at our institution, unless contra-
ndicated, for DVT prophylaxis. However, our study does
dd to the number of studies that report high rates of DVT
ormation despite LMWH prophylaxis. One possible expla-
ation is that the “prophylactic” dose of LMWH is not
dequate. It is interesting that LMWH is dosed by patient
eight when it is used therapeutically, but is given as a
tandard dose prophylactically regardless of patient weight.
herefore, one possible explanation of the differences be-
ween Geerts et al’s results and ours is that the populations
n Toronto, Canada in 1992 and Portland, Oregon in 2007
iffered in weight and therefore different pharmacologic
evels of LMWH were reached in the two populations. In
act, recent studies have shown that prophylactic dose
MWH does not reliably lower factor Xa levels in many
rauma patients and that trauma patients with higher factor
a levels are at higher risk of DVT development.16 Ran-
omized controlled trials of higher doses of LMWH for
VT prophylaxis are needed to assess the efficacy and safety
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guide management.
Studies cited in the ACCP guidelines report DVT rates
between 1% and 5% in trauma patients receiving LMWH
prophylaxis.9-13 This is dramatically lower than the rate
found in our study, 15.2%. This may be due to the fact that
our screening population included only critically ill trauma
patients and investigated for all lower extremity DVTs,
including CVDVTs. In a study cited by the ACCP to
recommend against routine DUS screening of trauma pa-
tients, Cippole et al found an overall DVT rate of 2% to 5%
in all trauma patients.9 However, in this study, only high-
risk patients received surveillance DUS screening while the
remainder of patients were examined clinically. The DVT
rate of the high-risk group in the Cippole study was 14% to
17%, which is very similar to the incidence found in our
study. Several other studies cited by the ACCP guidelines
also recommend against routine DUS screening of trauma
patients. Spain et al investigated duplex ultrasound scan-
ning of high-risk patients based on injury patterns. They
scanned patients only based on clinical suspicion and not
routinely. While their overall DVT rate was 5%, the rate of
positive duplex scans in the high-risk group was 35%.10
Schwarcz et al reported a 5% overall DVT rate in routine
scanning of high-risk trauma patients.11 Gastrocnemius
and soleal veins were not investigated and “high-risk”
patients were defined based on a scoring system of patient
and injury factors and patients were not necessarily critically ill.
Piotrowski et al also investigated DUS screening in high-
risk trauma patients.5 The overall LEDVT rate in this group
was 5.8%, and 85% were unsuspected clinically. This study
also did not investigate CVDVTs. Our rate of above knee
DVT was 5.7%, which is very similar to the rate reported by
this study; however, the majority of DVTs found in our
study were CVDVTs.
It has been suggested that anticoagulation can be de-
ferred in the acute setting of trauma patients without an
increased risk of LEDVT formation as long as intermittent
pneumatic compression devices are used and LMWH is
started 5 days after the injury.9 In our study, 30% of
LEDVTs were found within 1 week of admission. There-
fore, we recommend early screening of all critically ill
trauma patients. Ongoing surveillance would appear im-
portant to detect the remainder of LEDVTs that occur after
the first week of admission, 70% of all LEDVTs in our
study. In another study cited by the ACCP guidelines,
Borer et al report a similar rate of pulmonary embolism
regardless of routine DVT screening of orthopedic trauma
patients.17 However, in this study, screening was per-
formed only once during the hospitalization and within 3
days of admission. In our population, this screening proto-
col would have missed a substantial portion of DVTs and
may explain why the surveillance protocol used by Boer et
al was not effective at lowering pulmonary embolism rates.
One possible bias of our surveillance protocol is that
DUS screening studies are performed on Tuesdays and
Thursdays. Therefore, patients with longer ICU stays were
more likely to be present in the ICU during screening days ynd therefore more likely to undergo DUS screening. This
rotocol may self-select a more injured group of patients by
eing more likely to study patients with longer ICU LOS.
more individualized DUS screening schedule may result
n a lower rate of DVT detection within the trauma ICU by
ncluding more patients with shorter ICU length of stays.
he fact that incomplete DUS examinations were consid-
red negative for DVT may have underestimated the true
VT rates and the effect of long bone fractures on LEDVT
evelopment, as this group would have a higher rate of casts
nd hardware leading to incomplete examinations.
CVDVTs accounted for 62% of the DVTs found in our
tudy. Treatment of CVDVTs is not standardized, and
ften times CVDVTs are monitored but not treated with
nticoagulation. However, current ACCP guidelines rec-
mmend treatment of CVDVTs with full anticoagula-
ion,18 and several other studies have indicated that CVDVTs
ay be more harmful than previously thought. In a pro-
pective study of trauma patients, high-risk patients had a
4.1% incidence of CVDVTs on routine DUS screening.
ithin 4 to 8 days, 4.7% of CVDVTs propagated to an
bove knee position and 1.2% of patients had a pulmonary
mbolism when not anticoagulated.19 In contrast, patients
ith CVDVTs who receive therapeutic anticoagulation
eem to show zero or minimal rates of proximal propaga-
ion or pulmonary embolus.20,21 In our study 2 patients
ith calf vein DVTs developed CT scan confirmed pulmo-
ary embolus (PE). One of these patients was receiving
rophylactic dose LMWH at the time of PE development
nd the other patient was not receiving pharmacologic
rophylaxis. After diagnosis, 1 patient was immediately
nticoagulated with therapeutic LMWH (1mg/kg BID)
nd the other had an inferior vena cava (IVC) filter placed as
bridge to full anticoagulation. At the time of CVDVT
iagnosis, 15 patients were not receiving pharmacologic
rophylaxis. Ten of the 15 patients were placed on prophy-
actic dose LMWH after diagnosis of CVDVT. Three pa-
ients were placed on therapeutic LMWH after CVDVT
rophylaxis, and two patients were serially monitored with
US without addition of pharmacologic prophylaxis. In
ddition, two patients underwent IVC filter placement as a
ridge to therapeutic anticoagulation. One CVDVT (4%)
rogressed to the popliteal vein. This was in a patient not
eceiving pharmacologic prophylaxis. Upon extension of
is CVDVT to the popliteal vein he was therapeutically
nticoagulated.
In addition to the propagation and pulmonary embo-
ism risk of CVDVTs, postthrombotic syndrome also re-
ains a concern and presents with symptoms of pain,
dema, hyperpigmentation, and ulceration. Short-term follow-
p studies of isolated CVDVTs have shown that venous
eflux can be documented in 24% of patients with CVD-
Ts.22,23 Studies with longer follow-up have shown that
p to 39% of patients with isolated CVDVTs can develop
ymptoms of postthrombotic syndrome within 6 to 10
ears.24
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Current ACCP guidelines miss a substantial proportion of
LEDVTs in critically ill trauma patients, especially when
CVDVTs are included in the investigation. Routine DUS of
all critically ill trauma patients will detect a high number of
asymptomatic LEDVTs, 15.2% in our study. Diagnosis
of these otherwise undetected DVTs can lead to thera-
peutic anticoagulation, IVC filter placement, or contin-
ued surveillance depending on institutional practices.
DUS screening appears to be a useful adjunct to current
protocols of DVT prevention, detection, and treatment
in trauma ICUs. We recommend early and ongoing
surveillance of all critically ill trauma patients for all lower
extremity DVTs regardless of injury patterns, DVT risk
factors, or the presence of pharmacologic prophylaxis.
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Dr James Watson (Seattle, Wash). Dr Azarbal and his col-
leagues have reminded us that severely injured trauma patients arer symptoms concerning DVT with duplex ultrasound studies.
f those 264 asymptomatic patients, 40 (15%) had evidence of
VT and 25 (63%) of those were calf DVTs. This frequency of
VT is higher than that found by others1 and is similar to the
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September 2011748 Azarbal et al16.9% rate found in a systematic review of asymptomatic spinal
cord injury patients,2 a group at higher risk for DVT than
trauma patients.
It is not surprising that they found older patients and those
with a lower admission Glasgow Coma Score were more likely to
suffer a DVT and subsequently spend more time in the ICU than
those who did not develop a DVT. It is surprising that high-risk
injuries and higher injury severity scores did not correlate with a
higher risk of developing DVT.
Another unexpected finding was that the prophylactic admin-
istration of low molecular weight heparin did not provide any
protection against the development of DVT. We are not provided
any data about the timing of prophylaxis initiation or how fre-
quently anticoagulation was interrupted, either of which may
interfere with the efficacy of prophylaxis. It has been shown that
prophylaxis can safely be started within 36 hours of injury and need
not be interrupted for most surgical procedures due to concern
over excess bleeding.3
Cost data is of paramount importance in this economic cli-
mate. The authors appropriately point out that Meythaler showed
the cost per year of life saved for duplex scanning of brain injured
patients was only $2977,4 which is less than the cost of mammog-
raphy or fecal occult blood testing. The cost of “screening” for
asymptomatic patients is significant. I suspect we will, and should,
see a lot more specific economic data such as the “incremental cost
effectiveness ratio” of duplex scanning for various clinical situa-
tions in the near future. Providing good patient care is not enough
anymore. We need to ensure that what we do is not only medically
necessary but also that it makes economic sense for society.
I have several questions for the authors:
What is your current protocol for DVT prophylaxis in trauma
patients? Have you changed your recommendations in favor of
more aggressive prophylaxis? Do you think chemical prophylaxis
should be altered for operative procedures?
Dr Amir Azarbal. Thank you for your comments, Dr Wat-
son. Our current protocol is to start prophylactic dose LMWH at
30 mg SC bid as upon admission to the trauma ICU, unless there
is a contraindication. The decision to interrupt LMWH prophy-
laxis for procedures is left to the discretion of the surgeon perform-
ing the procedure. Most general surgical procedures are done
without interruption of the prophylaxis, while orthopedic and
neurosurgical procedures are more likely to result in a halting of
prophylaxis.
As for recommendations for more aggressive prophylaxis, we
have an ongoing study evaluating factor Xa levels and other objec-
tive measures of anticoagulation to help determine optimal levels
of LMWH prophylaxis in trauma patients. However this study is
still in its preliminary stages.DrWatson.How do you decide which asymptomatic patients
eed weekly scans? Do you only scan patients in the ICU or do you
lso include other high-risk patients with limited mobility who may
e in intermediate-care units or even on the regular ward?
Dr Azarbal.Currently, we scan all patients in the trauma ICU
eekly. Duplex ultrasound screening of ward patients considered
o be at high risk for developing DVTs is performed at the
iscretion of the trauma service attending and not done based on
rotocol.
Dr Watson. Does your lab get paid for screening venous
uplex examinations in asymptomatic patients?
DrAzarbal.No, screening studies are not currently reimburs-
ble and are done as part of a study protocol. Hopefully, with
ost-effectiveness data, such as the study by Meytheler et al4
creening studies will become reimbursable in the future.
Dr Watson. Are there any other tests you find useful in
etecting DVT? Specifically, would a positive or negative D-dimer
ssay have any effect on your decision to obtain, or not obtain a
uplex examination in an asymptomatic patient?
Dr Azarbal. D-dimer assays have been helpful due to their
igh negative predictive value in medical patients. However, in the
cute trauma setting the D-dimer assay can have a high false
egative rate.5 Therefore, given the high DVT rate of the trauma
CU population, I do not believe a normal D-dimer assay would be
ssuring enough to preclude duplex ultrasound screening. D-
imer assays may have more of a role in continued surveillance of
rauma patients as the time from injury increases.5 Conversely,
-dimer assays are often elevated in trauma patients; and therefore,
do not believe a positive D-dimer assay using current accepted
alues would be helpful.
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